Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 3
Submit an article Journal homepage
47
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly

Angela N Paisley Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
,
Peter Trainer Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
&
William Drake Department of Endocrinology, St Bartholomew’s Hospital, London, EC1A 7BE, UK. [email protected]
Pages 421-425 | Published online: 03 Mar 2005

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mark Hornyak & William T. Couldwell. (2009) Multimodality Treatment for Invasive Pituitary Adenomas. Postgraduate Medicine 121:2, pages 168-176.
Read now
Jens Bollerslev, Stine L Fougner & Jens P Berg. (2009) New directions in pharmacological treatment of acromegaly. Expert Opinion on Investigational Drugs 18:1, pages 13-22.
Read now

Articles from other publishers (11)

John J. Kopchick, Reetobrata Basu, Darlene E. Berryman, Jens O. L. Jorgensen, Gudmundur Johannsson & Vishwajeet Puri. (2022) Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Nature Reviews Endocrinology 18:9, pages 558-573.
Crossref
Reetobrata Basu, Yanrong Qian, Samuel Mathes, Joseph Terry, Nathan Arnett, Trent Riddell, Austin Stevens, Kevin Funk, Stephen Bell, Zac Bokal, Courtney Batten, Cole Smith, Isaac Mendez-Gibson, Silvana Duran-Ortiz, Grace Lach, Patricia Alexandra Mora-Criollo, Prateek Kulkarni, Emily Davis, Elizabeth Teaford, Darlene E. Berryman, Edward O. List, Sebastian Neggers & John J. Kopchick. (2022) Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo. Frontiers in Oncology 12.
Crossref
Letícia P. Leonart, Fernanda S. Tonin, Vinicius L. Ferreira, Fernando Fernandez-Llimos & Roberto Pontarolo. (2018) Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63:1, pages 18-26.
Crossref
Chieko Muto, Koji Chiba & Toshio Suwa. (2011) Population Pharmacokinetic and Pharmacodynamic Modeling of Pegvisomant in Asian and Western Acromegaly Patients. The Journal of Clinical Pharmacology 51:12, pages 1628-1643.
Crossref
Felisbina L. Queiroga, Dolores P?rez-Alenza, Gema Silvan, Laura Pe?a, Carlos S. Lopes & Juan C. Illera. (2010) Serum and intratumoural GH and IGF-I concentrations: Prognostic factors in the outcome of canine mammary cancer. Research in Veterinary Science 89:3, pages 396-403.
Crossref
Satoko Kojima, Masahiko Inahara, Hiroyoshi Suzuki, Tomohiko Ichikawa & Yuzo Furuya. (2009) Implications of insulin-like growth factor-I for prostate cancer therapies. International Journal of Urology 16:2, pages 161-167.
Crossref
Simoni A. KATERGARI, Athanasios MILOUSIS, Olga PAGONOPOULOU, Byron ASIMAKOPOULOS & Nikos K. NIKOLETTOS. (2008) Ghrelin in Pathological Conditions. Endocrine Journal 55:3, pages 439-453.
Crossref
Lucio Vilar, Mauro A. Czepielewsk, Luciana Ansaneli Naves, Guilherme A.F.S. Rollin, Luiz Augusto Casulari & Carlos E. Coelho. (2007) Substantial Shrinkage of Adenomas Cosecreting Growth Hormone and Prolactin with use of Cabergoline Therapy. Endocrine Practice 13:4, pages 396-402.
Crossref
Donghua Yin, Franzanne Vreeland, Larry J. Schaaf, Robert Millham, Barbara A. Duncan & Amarnath Sharma. (2007) Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy. Clinical Cancer Research 13:3, pages 1000-1009.
Crossref
Deepali Sachdev & Douglas Yee. (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics 6:1, pages 1-12.
Crossref
Jana Divisova, Isere Kuiatse, ZaWaunyka Lazard, Heidi Weiss, Franzanne Vreeland, Darryl L. Hadsell, Rachel Schiff, C. Kent Osborne & Adrian V. Lee. (2006) The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Research and Treatment 98:3, pages 315-327.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.